Literature DB >> 3898475

The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye.

N L Burstein.   

Abstract

Medications used in 'Dry Eye' patients are reviewed for their effects on the corneal surface including the overlying tear film. Preservatives are discussed, since they affect the properties of commercial preparations which may be instilled frequently as a substitute for normal tears. The major beneficial effect which a topically applied agent can have on epithelium is to supplement or stabilise the tear film. Thimerosal sometimes triggers a sensitivity reaction, and other mercurial compounds are unstable. Benzalkonium chloride compromises both corneal epithelium and tear film. Some cationic detergents, including chlorhexidine digluconate and polyquat, cause less disruption at prophylactic concentrations. The use of a small drop size is helpful in preventing toxic effects of preservatives. All preservatives should be avoided when unit doses of a sterile tear replacement, such as saline, can be made available. Topical antibiotics should be used only to control known bacterial infections, avoiding high concentrations of bacitracin, gentamicin, and neomycin. Steroids and antibiotic/steroid combinations must be used with great caution, and only when uncontrolled ocular inflammation justifies the risk of possible corneal ulceration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898475

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  18 in total

1.  Effects of long-term topical anti-glaucoma medications on meibomian glands.

Authors:  Reiko Arita; Kouzo Itoh; Shuji Maeda; Koshi Maeda; Ayumu Furuta; Atsuo Tomidokoro; Makoto Aihara; Shiro Amano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-02-18       Impact factor: 3.117

2.  Cytotoxicity assays of new artificial tears containing 2-methacryloyloxyethyl phosphorylcholine polymer for ocular surface cells.

Authors:  Masahiko Ayaki; Atsuo Iwasawa; Yoshimi Niwano
Journal:  Jpn J Ophthalmol       Date:  2011-08-10       Impact factor: 2.447

3.  Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients.

Authors:  D L Easty; G Nemeth-Wasmer; J-P Vounatsos; B Girard; N Besnainou; P Pouliquen; L Delval; J-F Rouland
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

4.  Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.

Authors:  P J Pisella; P Pouliquen; C Baudouin
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

5.  The effects of long-term topical glaucoma medication on conjunctival impression cytology.

Authors:  E Turaçli; K Budak; A Kaur; B Mizrak; C Ekinci
Journal:  Int Ophthalmol       Date:  1997       Impact factor: 2.031

6.  Electrical stimulation of auricular acupressure for dry eye: A randomized controlled-clinical trial.

Authors:  Jong Soo Lee; Sang Ho Hwang; Byung Cheul Shin; Young Min Park
Journal:  Chin J Integr Med       Date:  2016-04-13       Impact factor: 1.978

7.  Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies.

Authors:  A C Poon; G Geerling; J K Dart; G E Fraenkel; J T Daniels
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

8.  Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.

Authors:  Su Khoh-Reiter; Bart A Jessen
Journal:  BMC Ophthalmol       Date:  2009-07-28       Impact factor: 2.209

9.  Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2009-06-02

10.  Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease.

Authors:  B A Noble; R S K Loh; S MacLennan; K Pesudovs; A Reynolds; L R Bridges; J Burr; O Stewart; S Quereshi
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.